prostatic cancer
Conditions
Interventions
case series:NA
Sponsors
Zhongnan Hospital of Wuhan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Prostate adenocarcinoma diagnosed by pathology; 2. Considered as high-risk metastatic prostate cancer by imaging examination including PMSA-PET and bone scan: Gleason score >= 8, there are three or more lesions in bone scan, or there are measurable visceral metastasis except lymph node metastasis; 3. Have not received any anti-tumor treatment including androgen deprivation before; 4. ECOG score <= 2; 5. Prostate cancer tissues can be obtained for AR-V7 immunohistochemical staining; 6. Patients planned to be treated with androgen deprivation combined with abiraterone prednisone.
Exclusion criteria
Exclusion criteria: 1. Patients whose life expectancy is less than 1 year; 2. Patients who have serious mental illness or are unable to cooperate with treatment or follow-up due to other reasons; 3. Patients who fail to treat according to the doctor's instructions; 4. Patients with other tumor diseases; 5. Prostate cancer with pathological types other than adenocarcinoma; 6. Patients with severe allergy to gonadotropin releasing hormone (GnRH) analogues; 7. Blood testosterone could not reach castration level (<= 50ng/mL) during treatment; 8. Patients receiving immunosuppressive therapy or with immune deficiency diseases; 9. Patients with severe liver function damage (Child Pugh grade C); 10. Patients with severe renal function injury who need long-term dialysis treatment; 11. Patients with severe myelosuppression and severe neutropenia; 12. Participate in other clinical studies from 30 days before enrollment to the completion of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactHua Xu
Zhongnan Hospital of Wuhan University
Outcome results
None listed